vyndaqel
(tafamidis meglumine)Pfizer Laboratories Div Pfizer Inc
Usage: VYNDAQEL and VYNDAMAX are indicated for treating the cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, aiming to reduce cardiovascular mortality and related hospitalizations.